CMS Open Payments · Program Year 2024
FX Shoulder Solutions, Inc
FX Shoulder Solutions, Inc reported $1,214,847.17 across General Payments, Research, and Ownership to 657 physicians and teaching hospitals across 664 transactions.
- $1.2M
- All-tracks total
- 664
- Transactions
- 657
- Recipients
- +$130.2K
- General Payments vs PY2023
FX Shoulder Solutions, Inc reported $1,214,847.17 across all CMS Open Payments tracks (General + Research + Ownership) to 657 physicians and teaching hospitals in Program Year 2024 - ranking #576 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $525,484.41, averaging $1.8K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer fx-shoulder-solutions-inc FX Shoulder Solutions, Inc
$1.2M · #576/1,925 · 0.0% industry · PY2024
- TOT $1.2M
- RANK #576
- SHARE 0.0%
- TXN 664
- RCP 657
- CAT 7
- GEN $525.5K
- ΔGEN +$130.2K
- TOP1 17.7%
- PY 2024
Volume peers
Nearest volume peer: Agilent Technologies, Inc. ($1.2M)
FX Shoulder Solutions, Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
FX Shoulder Solutions, Inc's CMS-reported General Payments increased by $130.2K (+32.9%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: FX SHOULDER SOLUTIONS, INCPY2023: FX SHOULDER SOLUTIONS, INCPY2024: FX Shoulder Solutions, Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $395,261.81
- PY2024
- $525,484.41
What the Data Shows for FX Shoulder Solutions, Inc
Rank #576 of 1,925 companies in CMS Open Payments for 2024 belongs to FX Shoulder Solutions, Inc, which reported $1,214,847.17 across 664 transactions to 657 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $1.8K per transaction and $1.8K per recipient.
46 transactions worth $239.2K make "Royalty or License" the top general-payment category in the 7-category breakdown below, 45.5% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 7 types of general payments, FX Shoulder Solutions, Inc's largest category was "Royalty or License" at $239.2K - 45.5% of General Payments.
FX Shoulder Solutions, Inc reports 7 general-payment categories - the top three are Royalty or License (45.5%), Travel and Lodging (20.0%), and Honoraria (15.4%). The remaining 4 categories make up 19.0% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How FX Shoulder Solutions, Inc divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Royalty or License | $239.2K | 46 | 45.5% |
| Travel and Lodging | $105.3K | 296 | 20.0% |
| Honoraria | $81.0K | 31 | 15.4% |
| Consulting Fee | $41.9K | 18 | 8.0% |
| Grant | $34.0K | 6 | 6.5% |
| Food and Beverage | $23.5K | 257 | 4.5% |
| Education | $550.01 | 3 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $322,511.83 (61.4%) of $525,484.41 in this company's General Payments records across 139 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for FX Shoulder Solutions, Inc
The five named recipients with the highest reported General Payments from this company
- 1
umasuthan srikumaran
$93,205.60 across 68 reported transactions
- 2
howard walker harris
$75,099.55 across 42 reported transactions
- 3
michael bradley
$53,802.74 across 14 reported transactions
- 4
Todd C Moen
$50,847.18 across 14 reported transactions
- 5
alfred cook
$49,556.76 across 17 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as FX Shoulder Solutions, Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about FX Shoulder Solutions, Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with FX Shoulder Solutions, Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Perspectum Diagnostics Ltd
Spinal Surgical Strategies, Inc.
Anika Therapeutics, Inc.
Braeburn Inc.
Pulmonx Corporation
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.